2017
Breastfeeding and Endometrial Cancer Risk
Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, Chen C, Cook LS, Dal Maso L, De Vivo I, Freudenheim JL, Friedenreich CM, La Vecchia C, McCann SE, Moysich KB, Lu L, Olson SH, Palmer JR, Petruzella S, Pike MC, Rebbeck TR, Ricceri F, Risch HA, Sacerdote C, Setiawan VW, Sponholtz TR, Shu XO, Spurdle AB, Weiderpass E, Wentzensen N, Yang HP, Yu H, Webb PM. Breastfeeding and Endometrial Cancer Risk. Obstetrics And Gynecology 2017, 129: 1059-1067. PMID: 28486362, PMCID: PMC5473170, DOI: 10.1097/aog.0000000000002057.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskOdds ratioStudy-specific odds ratiosEndometrial Cancer ConsortiumBody mass indexMultivariable logistic regressionConfidence intervalsCase-control studyMaternal benefitsNulliparous womenHistologic subtypeMass indexCommon cancerLower riskStudy heterogeneityCancer ConsortiumControl groupCancerLogistic regressionAverage durationLonger average durationWomenBreastfeeding
2014
Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging
Menderes G, Azodi M, Clark L, Xu X, Lu L, Ratner E, Schwartz PE, Rutherford TJ, Santin AD, Silasi DA. Impact of Body Mass Index on Surgical Outcomes and Analysis of Disease Recurrence for Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging. International Journal Of Gynecological Cancer 2014, 24: 1118-1125. PMID: 24927247, DOI: 10.1097/igc.0000000000000156.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedAged, 80 and overBody Mass IndexCarcinosarcomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyLymph Node ExcisionLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesRoboticsSurvival RateConceptsBody mass indexRecurrence-free survivalRobotic-assisted stagingEndometrial cancerRecurrence rateDisease recurrenceMass indexMean postoperative hospitalizationLymph node countMean operative timeLong-term outcomesNonendometrioid cancersMorbid obesityPostoperative hospitalizationMetastatic diseaseNonendometrioid histologyObese patientsOverall survivalConsecutive patientsOperative outcomesHistologic subtypeOperative timeSurgical outcomesEndometrioid carcinomaMean age
2012
Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium
Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, Brinton LA, Cai H, Cerhan JR, Cozen W, Chen C, Doherty J, Freudenheim JL, Goodman MT, Hankinson SE, Lacey JV, Liang X, Lissowska J, Lu L, Lurie G, Mack T, Matsuno RK, McCann S, Moysich KB, Olson SH, Rastogi R, Rebbeck TR, Risch H, Robien K, Schairer C, Shu XO, Spurdle AB, Strom BL, Thompson PJ, Ursin G, Webb PM, Weiss NS, Wentzensen N, Xiang YB, Yang HP, Yu H, Horn-Ross PL, De Vivo I, Group T. Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. American Journal Of Epidemiology 2012, 176: 269-278. PMID: 22831825, PMCID: PMC3491967, DOI: 10.1093/aje/kws129.Peer-Reviewed Original ResearchConceptsEndometrial Cancer ConsortiumEndometrial cancerLast birthCancer ConsortiumLarge pooled analysisTumor histologic subtypeEndometrial cancer riskExogenous hormone useBody mass indexPooled odds ratioCase-control studyYears of ageHormone useHistologic subtypeMass indexPooled analysisRisk factorsEffect modificationOdds ratioDiagnosis groupsProtective associationCancer riskLower riskNumber of birthsOlder age
2011
Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression
Varughese J, Hui P, Lu L, Yu H, Schwartz PE. Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression. Journal Of Oncology 2011, 2011: 628084. PMID: 22187554, PMCID: PMC3236522, DOI: 10.1155/2011/628084.Peer-Reviewed Original ResearchProgression-free survivalClear cell cancerOverall survivalCell cancerUterine cancerAggressive histologic subtypeRetrospective chart reviewSingle institution experiencePlatinum-based chemotherapyAdvanced-stage patientsSingle academic institutionAdjuvant therapyChart reviewFIGO stageWorse survivalUterine corpusClinicopathologic featuresHistologic subtypePoor prognosisTreatment regimensExcellent survivalDisease progressionTreatment strategiesClinicopathologic parametersInnovative therapies